文献速递慢性肾脏病

经活检证实的代谢功能障碍相关脂肪性肝病患者的慢性肾脏病风险

Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Nephrol Dial Transplant · 2026-06-23

MASLD患者发生复合肾脏结局的风险显著增高(aHR 1.85,95%CI 1.68-2.04),且风险随组织学严重程度加重而增加。

要点

  • 经活检证实的MASLD患者CKD复合结局风险较一般人群增加85%。
  • MASLD患者KFRT风险增加近3倍(aHR 2.88)。
  • CKD风险随MASLD组织学严重程度加重而增加(Ptrend<0.001)。

核心结论

  • 经活检证实的MASLD患者较一般人群和同胞均具有更高的CKD发生风险。
  • 超额风险在所有组织学阶段均存在,并随组织学严重程度加重而增加。

研究设计与样本

  • 主要终点为 incident CKD、KFRT(启动透析或肾移植)或肾脏疾病死亡组成的复合终点,采用多变量Cox回归估计aHR。
  • 另将至少有1名同胞的MASLD患者与其全同胞进行比较。

主要发现

  • 相当于每39例MASLD患者随访10年增加1例复合结局事件,aHR 1.85(95%CI 1.68-2.04)。
  • HR随MASLD组织学严重程度加重而增加(Ptrend<0.001)。
  • MASLD患者CKD风险aHR 1.83(95%CI 1.66-2.02),KFRT风险aHR 2.88(95%CI 2.32-3.57)。
  • 敏感性分析和二次分析结果稳健,包括与全同胞比较时。

临床怎么用

  • 对经活检证实的MASLD患者,应关注CKD风险,尤其组织学严重程度较高者。
  • MASLD患者可能需要定期监测肾功能,以便早期发现CKD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: There is scarce long-term data on the risk of chronic kidney disease (CKD) in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). We hypothesize that the risk of CKD in MASLD is increased and may vary with worsening histological severity. METHODS: Nationwide matched cohort study including all Swedish adults with histologically confirmed MASLD from 1969 to 2017 (n = 11 082) without prior kidney disease [simple steatosis (n = 7 522), non-fibrotic metabolic dysfunction-associated steatohepatitis (MASH) (n = 1 257), non-cirrhotic fibrosis (n = 1 692) and cirrhosis (n = 611)]. Individuals were matched to ≤ 5 population comparators (n = 52 645). The primary endpoint consisted of incident CKD, kidney failure with replacement therapy (KFRT; initiation of dialysis or kidney transplant) or death from kidney disease. Multivariable Cox regression was used to estimate adjusted hazard ratios (aHRs). Individuals with MASLD with at least one sibling were compared to their full siblings. RESULTS: Over a median of 17.6 years, 878 individuals with MASLD (incidence rate [IR] 53.1/10 000 person-years) vs. 2 643 comparators (IR 27.4) developed the composite CKD outcome. This was equal to one additional composite outcome event in 39 individuals with MASLD followed for ten years and corresponded to an aHR of 1.85 (95% confidence interval [CI] 1.68 - 2.04). The HR increased with worsening histological severity of MASLD (Ptrend < 0.001). Individuals with MASLD were at an almost two-fold increased hazard of CKD (aHR 1.83; 95% CI 1.66 - 2.02) and three-fold increased hazard of KFRT (aHR 2.88; 95% CI 2.32 - 3.57). Findings were robust and consistent across sensitivity and secondary analyses, including when individuals with MASLD were compared to their full biological siblings. CONCLUSION: Individuals with biopsy-proven MASLD were at higher risk of developing CKD compared to both the general population and siblings. Excess risks were evident across all histological stages of MASLD and increased with worsening histologic severity.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ebrahimi F, Eichhorn C, Simon TG, et al. Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease. Nephrol Dial Transplant. 2026. PMID: 42335946. doi:10.1093/ndt/gfag147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。